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PTENMicroRNAs (miRNAs) regulate gene expression by targeted repression of transcription and transla-
tion, and are involved in carcinogenesis. In this study, we demonstrated that the expression of
miR-454 was up-regulated in uveal melanoma tissues compared to normal tissues. Ectopic expres-
sion of miR-454 resulted in significant promotion of cell proliferation, colony formation, invasion
and induction of cell cycle in uveal melanoma cells. Furthermore, we identified PTEN as a direct tar-
get of miR-454. Our data revealed that ectopic expression of PTEN restored the effects of miR-454 on
cell proliferation and invasion in uveal melanoma cells. These findings support an oncogene role of
miR-454 in development of uveal melanoma.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Uveal melanoma is the most common malignancy of the eye. It
is arising out of pigmented cells including the ciliary body, choroid,
or iris [1–4]. The annual incidence of uveal melanoma is five to
seven cases per million populations [5–7]. Metastatic disease of
the liver accounts for the high death rate of uveal melanoma, with
up to 50% of patients having liver metastases [8–11]. Currently, the
etiology and pathogenic mechanism of uveal melanoma are still
not elucidated. Therefore, it is important to identify the new crucial
biomarkers for early prognosis and therapeutic targets [12–14].
MicroRNAs (miRNAs) are a class 18–22 nucleotide-length non-
coding RNAs that are involved in posttranslational regulation of
gene expression by repressing translation or cleaving RNA tran-
scripts in a sequence-specific manner [15–18]. A growing body of
evidence suggests that miRNAs play crucial roles in variousphysiological and pathological processes, including development,
cell differentiation, proliferation, apoptosis, migration and signal
transduction [19–22]. Recent evidence also identifies muted or
aberrantly expressed miRNAs in various human cancers such as
gastric cancer, bladder cancer, breast cancer, osteosarcoma, hepa-
tocellular carcinoma and Ewing’s sarcoma, indicating that miRNAs
can function as tumor suppressors or oncogenes [23–29].
The expression of miR-454 was reported to be upregulated in
human colorectal cancer tissues and cell lines, functioning as a
novel oncogenic miRNA contributing to colon tumorigenesis by
regulating TGF-b/Smad signaling by targeting Smad4 [30].
Moreover, another study showed that the expression of miR-454
was downregulated in the TGF-b1-treated LX-2 cells and miR-
454 could inhibit the activation of hepatic stellate cells (HSCs) by
directly targeting Smad4 [31]. However, the expression and role
of the miR-454 in the uveal melanoma development and
progression remain unknown. In our study, we demonstrated that
miR-454 acted as an oncogene in uveal melanoma. The expression
of miR-454 was upregulated in uveal melanoma tissues compared
to normal tissues and this was also observed in uveal melanoma
cells and human melanocyte cell line. Ectopic expression of
miR-454 resulted in significant promotion of cell proliferation,
colony formation, invasion and induction of cell cycle in uveal mel-
anoma cells. Furthermore, we identified PTEN as a direct target of
miR-454.
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2.1. Ethics statement
All patients provided written informed consent for this study
and this study was also approved by the Medical Ethics Committee
of The Fourth Hospital of Harbin Medical University.
2.2. Tissue specimens and cell lines
Tumor samples and their morphologically normal tissues (loca-
ted > 0.3 cm from the tumor) were obtained from 25 uveal mela-
noma patients and were immediately frozen in liquid nitrogen.
Human uveal melanoma cell lines (OCM-1A, MUM-2C, C918 and
MUM-2B) and human melanocyte cell line (D78) were obtained
from the Cell Bank of the Chinese Academy of Sciences (Beijing,
People’s Republic of China). The OCM-1A, MUM-2C and D78 cells
were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (FBS), and MUM-2B, C918 in
RPMI 1640.
2.3. RNA preparation and quantitative real-time PCR (qPCR) assay
Total RNA was extracted from tissues or cells using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) following to the manufac-
turer’s instruction. Quantitative real-time PCR was performed
using SYBR Premix Ex Taq II (TaKaRa). TaqMan microRNA assays
(Applied Biosystems, Foster City, California, USA) were used to
quantify the expression levels of miR-454. Forward and reverse
primers were used as follows: PTEN, CACCTATTCCTCAGCCCTTAT
and AACCCTCATTCAGACCTTCAC; GAPDH, AATGGGCAGCCGTTAGG
AAA and TGAAGGGGTCATTGATGGCA; miR-454, ACCCTATCAA
TATTGTCTCTGC and GCGAGCACAGAATTAATACGAC; U6, CGCTTCG
GCAGCACATATACTA and CGCTTCACGAATTTGCGTGTCA.
2.4. Oligonucleotide transfection
miR-454 mimics and scramble were obtained by Genepharma
(Genepharm, Shanghai, China). PTEN vector were synthesized by
RiboBio (RiboBio, Guangzhou, China). Cells were transfected with
oligonucleotides using Lipofectamine 2000 Reagent (Invitrogen
Life Technologies) following the manufacturer’s instructions.
2.5. Cell proliferation, colony formation and cell cycle assay
Cell proliferation was performed using a Cell Counting Kit-8
(CCK-8) (Dojindo, Kumamoto, Japan) according to the manufac-
turer’s instructions and cell numbers were counted by the optical
density at 450 nm. For colony formation assay, cells were cultured
in a 6-well plate and seeded for 10 days. Colonies were fixed with
paraformaldehyde and stained with 1% crystal violet (Sigma–
Aldrich) and the numbers of colonies were counted. The fixed cells
were incubated with propidium iodide (PI) and ribonuclease A for
30 min, and then detected by flow cytometric analysis using FL2
histogram of a flow cytometer (FACSort; Becton–Dickinson, San
Jose, CA, USA).
2.6. Cell invasion assay
Invasion assay was performed using Matrigel invasion chamber
system (BD Biosciences, Bedford, MA). Cells were cultured on the
top of matrigel-coated chambers in a serum-free medium and
DMEM containing 10% FBS was used as a chemoattractant.
Invasion of cells to the lower side were fixed and stained with %
crystal violet (Sigma–Aldrich) and were counted.2.7. Western blot analysis
Proteins were extracted from cells using Protein Extraction Kit
(KeyGen, Nanjing, China) and were separated on 10% sodium dode-
cyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) and
transferred to nitrocellulose membrane (Bio-Rad, Hercules, Califor-
nia, USA). The membranes were blocked for 1 h with 5% non-fat
milk and then detected with primary antibodies recognizing PTEN
(Abcam, Cambridge, MA, USA), mouse anti-GAPDH antibody
(1:3000; Sigma–Aldrich), respectively. Proteins were detected with
enhanced chemiluminescence reagents (Thermo Scientific,
Waltham, Massachusetts, USA) after incubation with appropriate
horseradish peroxidase (HRP)-conjugated secondary antibodies
(Jackson ImmunoResearch).
2.8. Luciferase reporter assay
The mutated (MUT) and wild-type (WT) putative miR-454 tar-
get on PTEN 30UTR were cloned into the pGL3 Dual-Luciferase
miRNA Target Expression Vector (Invitrogen Corporation).
Luciferase activity was performed using the Dual-Luciferase
Reporter Assay System (Promega) according to manuscript’s
instruction.
2.9. Statistical analysis
SPSS16.0 (Chicago, IL, USA) was performed for statistical analy-
sis. Data were presented as the mean ± standard deviation (S.D.)
from at least three independent experiments. Student’s t-test or a
one-way analysis of variance (ANOVA) was used to evaluate the
statistical significance of the results. Differences were considered
statistically significant at P < 0.05.
3. Result
3.1. The expression of miR-454 was upregulated in uveal melanoma
tissues and cell
The expression of miR-454 was upregulated in uveal melanoma
samples compared to their normal samples (Fig. 1A). Further
results confirmed that miR-454 was upregulated in uveal mela-
noma (OCM-1A, MUM-2C, C918 and MUM-2B) compared to
human melanocyte cell line (D78) (Fig. 1B).
3.2. MiR-454 promoted the uveal melanoma cell proliferation and
invasion
To measure the functional role of miR-454 overexpression in
uveal melanoma, we transfected uveal melanoma cell line MUM-
2B with miR-454 mimic (Fig. 2A). Ectopic expression of miR-454
promoted cell proliferation as compared to cells expressing scram-
ble (Fig. 2B). Cell cycle analysis revealed that overexpression of
miR-454 decreased the number of cells in the G0/G1 phase of the
cell cycle while the S-phase population increased in MUM-2B cells
(Fig. 2C). Colony formation assay also showed that ectopic expres-
sion of miR-454 increased the MUM-2B cell colony formation
(Fig. 2D). Invasion assay analysis demonstrated that miR-454 over-
expression promoted the MUM-2B cell invasion (Fig. 2E).
3.3. PTEN was a direct target of miR-454 in uveal melanoma
We used TargetScan to find that 30UTR of PTEN contained the
highly conserved putative miR-454 binding sites (Fig. 3A).
Luciferase reporter analysis demonstrated that overexpression of
miR-454 reduced luciferase activity in the PTEN wild-type reporter
Fig. 1. The expression of miR-454 was up-regulated in uveal melanoma tissues and cell. (A) miR-454 was detected in 25 uveal melanoma samples by qRT-PCR. Data
demonstrated that the expression of miR-454 was found to be up-regulated in uveal melanoma samples compared to their normal samples. (B) The expression of miR-454
was measured in uveal melanoma (OCM-1A, MUM-2C, C918 and MUM-2B) and uman melanocyte cell line (D78) using qRT-PCR. ***P < 0.001.
Fig. 2. miR-454 promoted the uveal melanoma cell proliferation and invasion. (A) The expression of miR-454 was measured in uveal melanoma cell MUM-2B after
transfected by miR-454 mimic or scramble. (B) CCK8 assay was measured the MUM-2B cell proliferation after transfected by miR-454 mimic or scramble. (C) Cell cycle
analysis was measured the MUM-2B cell cycle after transfected by miR-454 mimic or scramble. (D) Colony formation analysis was measured the MUM-2B cell colony
formation after transfected by miR-454 mimic or scramble. (E) Invasion analysis was measured the MUM-2B cell invasion after transfected by miR-454 mimic or scramble.
**P < 0.01 and ***P < 0.001.
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Fig. 3. PTEN was a direct target of miR-454 in MUM-2B cell. (A) TargetScan was
demonstrated that 30UTR of PTEN contained the highly conserved putative miR-454
binding sites. (B) Luciferase reporter analysis demonstrated that overexpression of
miR-454 reduced luciferase activity in the PTEN wild-type reporter gene but not the
mutant type in MUM-2B cell. (C) Ectopic expression of miR-454 inhibited the
protein expression of PTEN in MUM-2B cell.
Fig. 4. miR-454 inhibited the expression of AKT and MTOR. (A) Western blot
analysis was measured the protein level of AKT and phospho-AKT (p-AKT) after
transfected by miR-454 mimic or scramble in MUM-2B cell. (B) Western blot
analysis was measured the protein level of MTOR and phospho-MTOR (p-MTOR)
after transfected by miR-454 mimic or scramble in MUM-2B cell.
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targeted the PTEN 30UTR (Fig. 3B). Ectopic expression of miR-454
inhibited the expression of PTEN (Fig. 3C).
3.4. MiR-454 inhibited the expression of AKT and MTOR
Ectopic expression of miR-454 promoted the expression of AKT,
phospho-AKT (p-AKT), MTOR, and phospho-MTOR (p-MTOR) com-
pared to cells expressing scramble (Fig. 4A and B).
3.5. Ectopic expression of PTEN restored the effects of miR-454 on cell
proliferation and invasion in uveal melanoma cells
Western blot analysis demonstrated that PTEN expression was
restored after transfection of cells with the PTEN vector (Fig. 5A).
Overexpression of PTEN vector promoted MUM-2B cells prolifera-
tion and invasion (Fig. 5B and C).
4. Discussion
Increasing evidences demonstrate that miRNAs have a regula-
tory role in the development and progression of human cancers
through the suppression of genes involved in cell proliferation, dif-
ferentiation, invasion and migration [32–39]. Our previous study
has shown that miR-144 acts as a tumor suppressor in uveal
melanoma [40]. Moreover, Liu et al. demonstrated that miR-9 sup-
pressed uveal melanoma cell migration and invasion partly
through downregulation of the NF-jB1 signaling pathway [8].
Yan et al. showed that miR-182 functioned as a potent tumor sup-
pressor in uveal melanoma cells [14]. miR-34b and miR-34c act as
tumor suppressor genes in uveal melanoma cell proliferation and
migration [11]. In our study, the expression of miR-454 was upreg-
ulated in uveal melanoma tissues compared to normal tissues and
this was also observed in uveal melanoma cells and human mela-
nocyte cell line. Ectopic expression of miR-454 promoted cell pro-
liferation, colony formation, invasion and induction of cell cycle in
uveal melanoma cells. Furthermore, we identified PTEN as a direct
target of miR-454. Our data revealed that ectopic expression of
PTEN restored the effects of miR-454 on cell proliferation and inva-
sion in uveal melanoma cells. These findings suggest that miR-454
may be an oncogene that controls PTEN expression in uveal mela-
noma cells.The expression of miR-454 was reported to be upregulated in
human colorectal cancer tissues and cell lines, functioning as a
novel oncogenic miRNA contributing to colon tumorigenesis by
regulating TGF-b/Smad signaling by targeting Smad4 [30]. More-
over, another study showed that the expression of miR-454 was
downregulated in the TGF-b1-treated LX-2 cells and miR-454 could
inhibit the activation of hepatic stellate cells (HSCs) by directly tar-
geting Smad4 [31]. However, the expression and role of the miR-
454 in the uveal melanoma development and progression remain
unknown. In our study, the expression of miR-454 was higher in
uveal melanoma tissues compared to normal tissues and this was
also observed in uveal melanoma cells and human melanocyte cell
line. Furthermore, overexpression of miR-454 promoted cell prolif-
eration, colony formation, invasion and induction of cell cycle in
uveal melanoma cells. These data suggested that miR-454 acted
as an oncogene role in the development and progression of uveal
melanoma.
Next, we investigated the molecular mechanism of miR-454 in
promoting proliferation and metastasis in uveal melanoma cells.
We used TargetScan to find that 30UTR of PTEN contained the
highly conserved putative miR-454 binding sites. Next, we demon-
strated that miR-454 overexpression was associated with suppres-
sion of luciferase activity. In addition, we observed that the level of
PTEN protein was decreased after miR-454 overexpression. We
also demonstrated that overexpression of miR-454 enhanced the
expression of AKT, phospho-AKT (p-AKT), MTOR, and phospho-
MTOR (p-MTOR), which is line with the functional of PTEN down-
regulation [41]. Functional assays by PTEN vector transfection
restored the effects of miR-454 on cell proliferation and invasion
in uveal melanoma cells. PTEN was discovered as a tumor suppres-
sor gene and played a critical factor in the development and pro-
gression of various cancers including gastric cancer,
osteosarcoma, colon cancer, nasopharyngeal carcinoma and pros-
tate cancer [42–46]. Previous studies also showed that PTEN was
a tumor suppressor involved in uveal melanoma pathogenesis
and might be associated with clinical outcome [47]. Homozygous
deletions and intragenic mutations of PTEN occurred more fre-
quently in the metastatic cutaneous melanomas and cell lines
[48]. However, the mechanism of PTEN downregulation in uveal
melanoma is still unknown. The ability of miR-454 to target PTEN
may provide one such mechanism of post-transcriptional control
of PTEN.
Some limitations of our study have to be improved in the fur-
ther work. First, the sample size of the uveal melanoma tissues
was small. Second, both these tumor tissues and control tissues
contained melanoma cells and an admixture of stroma cells like
macrophages, granulocytes and other matrix cells. The density of
these cells may be much higher in the tumor tissues than in the
control tissues and this may affect the results. Moreover, it is
essential to study the role of miR-454 in more other cancers such
as gastric cancer, breast cancer, hepatocellular carcinoma and lung
cancer in next work.
Fig. 5. The ectopic expression of PTEN restored the effects of miR-454 on cell proliferation and invasion in uveal melanoma cells. (A) Western blot analysis was measured the
protein level of PTEN in the MUM-2B cells after transfection of cells with the PTEN vector. (B) CCK8 assay was measured the miR-454 overexpressing MUM-2B cell
proliferation after transfected PTEN vector or control. (C) Invasion assay was measured the miR-454 overexpressing MUM-2B cell invasion after transfected PTEN vector or
control. **P < 0.01 and ***P < 0.001.
L. Sun et al. / FEBS Letters 589 (2015) 2791–2796 2795In conclusion, we demonstrated that miR-454 was frequently
overexpressed in uveal melanoma tissues and cell lines. MiR-454
played an important role in the malignant progression of uveal
melanoma cells by directly regulating PTEN expression. Our find-
ings suggested that miR-454 might be used as a potential thera-
peutic target for the treatment of patients with uveal melanoma.Acknowledgement
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